Artrya Limited (AU:AYA) has released an update.
Artrya Limited has initiated commercial operations in Australia, partnering with The Cardiac Centre NSW, and is extending its U.S. presence through strategic partnerships, ahead of anticipated FDA approval. The company, specialized in AI-based coronary artery disease diagnosis, is also exploring new markets following TGA approval. With a strong cash position, Artrya expects to generate first revenues in Australia in the next quarter and is advancing its commercialization efforts with pilot programs in various jurisdictions.
For further insights into AU:AYA stock, check out TipRanks’ Stock Analysis page.
